357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO, CA
Market cap: $2.0B (2/09/2026)
Price: $5.71
Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan, Investor Presentation
Investor Presentation
Reports Third Quarter 2025 Financial Results and Provides Business Update
Earnings Release
Shareholder votes
Q3
Q2
Q1
FY 2024
FY 2023 amended
FY 2023
S-3ASR
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRER14A
PRE 14A
Notification Filed by a National Security Exchange
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Definitive Revised Proxy Statement
Post-Effective Amendment to Registration Statement